Physician

Vinod Doreswamy, M.D.

According to 2025 Medicare claims, Vinod Doreswamy, M.D. (NPI: 1689696577) practices allergy/immunology in the Seattle-Bellevue-Kent, WA market, with the plurality of this provider's patient population coming from King, WA. This provider's primary affiliated billing organization is THE POLYCLINIC PLLC (NPI: 1174594634; TIN: 910369070) and primary practice location at 98115-2062. Doreswamy is affiliated with the CareMount Value Partners IPA (ACO ID: D0019), participating under the REACH model.

Doreswamy's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 250 traditional Medicare patients, billed 123,438 HCPCS/CPT codes, and received $1,256,450 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 659 prescription claims across 130 beneficiaries totaling $308,145 in drug costs, led by Dupixent Syringe (Dupilumab). DME data shows 40 claims. Open Payments data shows 2 records totaling $163. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $96,948 to $1,256,450. Similarly, Part D prescription costs have moved sharply higher in recent years, from $35,039 to $308,145. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	136	6,062	$96,948
2016	176	8,431	$152,990
2017	160	9,073	$179,214
2018	183	10,452	$226,847
2019	186	10,716	$215,995
2020	145	6,987	$165,271
2021	192	14,272	$339,012
2022	220	40,189	$566,230
2023	285	132,698	$1,347,019
2024	250	123,438	$1,256,450

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	86	305	$35,039
2016	102	449	$53,171
2017	122	505	$85,048
2018	139	537	$89,688
2019	137	586	$88,480
2020	124	635	$110,660
2021	155	610	$95,077
2022	139	630	$160,238
2023	124	637	$226,326
2024	130	659	$308,145

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	68	$132,278
2021	N/R	49	$110,616
2022	N/R	52	$128,450
2023	N/R	75	$135,522
2024	N/R	40	$104,328

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	59	92	$100
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	114	441	$57
36415	Insertion of needle into vein for collection of blood sample	41	100	$9
J3489	Injection, zoledronic acid, 1 mg	42	210	$4
J7050	Infusion, normal saline solution, 250 cc	40	95	$0

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Dupixent Syringe	Dupilumab	27	756	$104,471
Dupixent Pen	Dupilumab	13	364	$48,350
Xolair	Omalizumab	13	364	$41,761
Breo Ellipta	Fluticasone/Vilanterol	46	2,220	$29,149
Spiriva Respimat	Tiotropium Bromide	11	690	$11,865

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1566	Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg	N	N/R	12	$59,845
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	N	N/R	14	$39,867
Q2052	Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)	N	N/R	14	$4,615

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$163	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Vinod Doreswamy, M.D.?

Tedicare shows public-source Medicare data for Vinod Doreswamy, M.D. (NPI 1689696577), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Vinod Doreswamy, M.D. have ACO affiliation data?

Vinod Doreswamy, M.D. is shown with ACO affiliation data for CareMount Value Partners IPA (REACH, ACO ID D0019).

What billing organization is linked to Vinod Doreswamy, M.D.?

Vinod Doreswamy, M.D. is linked to THE POLYCLINIC PLLC (billing NPI 1174594634) in the available physician profile data.

Does Vinod Doreswamy, M.D. have Open Payments data?

Vinod Doreswamy, M.D. has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.